BRTX Biorestorative Therapies
- 1.480
- +0.010+0.68%
Biorestorative Therapies News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Express News | BioRestorative Therapies Inc - Patent Protection Expected Until April 29, 2040
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem Metabolic Disease Program
Express News | BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting Thermostem® Metabolic Disease Program
Maxim Group Maintains Biorestorative Therapies(BRTX.US) With Buy Rating, Maintains Target Price $6
Positive Outlook for BioRestorative Therapies: Phase 2 Trial Results Drive Buy Rating
Roth MKM Remains a Buy on BioRestorative Therapies (BRTX)
BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript Summary
BioRestorative Therapies Showcases Promising Stem Cell Advances
Biorestorative Therapies | 8-K: BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
BioRestorative Therapies GAAP EPS of -$0.13 Beats by $0.30
BioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased Function
Express News | BioRestorative Therapies Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Revenue Results. Additionally, the Company Reported Preliminary Phase 2 BRTX-100 Clinical Data Showing a Material Decrease in Pain and Increased Function
Express News | BioRestorative Therapies Inc - Patient Reported Efficacy Outcomes Show a Material Decrease in Pain and Increase in Function
Biorestorative Therapies | 10-Q: Q3 2024 Earnings Report
BioRestorative Therapies 3Q Loss/Shr 13c >BRTX
Express News | BioRestorative Therapies Q3 Operating Income USD -2.3 Million
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
Earnings Preview: BRTX to Report Financial Results Post-market on November 13
BioRestorative Therapies to Announce Phase 2 Trial Data
No Data